| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 63,36 | +0,48 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
| CSPC PHARMA | 0,816 | +1,53 % | CSPC PHARMA KN026 Combined with HB1801 for Breast Cancer Meets Primary Endpoint | ||
| SELLAS LIFE SCIENCES | 6,880 | +1,78 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 408,80 | -1,66 % | Madrigal takes giant inflatable liver on US tour in disease awareness push | ||
| ACADIA PHARMACEUTICALS | 18,525 | +1,62 % | ACADIA PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| CATALYST PHARMACEUTICALS | 27,000 | -0,74 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| METRIOPHARM | - | - | Press Release: MetrioPharm AG: Prof. Dr. med. Jürgen Braun Appointed as New Member of the Scientific Advisory Board | Press Release: MetrioPharm AG: Prof. Dr. med. Jürgen Braun Appointed as New Member of the Scientific Advisory Board
-- Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of
MetrioPharm... ► Artikel lesen | |
| OPUS GENETICS | 3,360 | -3,45 % | Opus Genetics, Inc.: Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program | RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product | Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
| SAVARA | 4,460 | -2,00 % | Savara CFO to step down | ||
| GALECTIN THERAPEUTICS | 2,200 | -5,17 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,030 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,030 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule | ||
| CIPHER PHARMACEUTICALS | 9,850 | +0,51 % | Cipher Pharmaceuticals GAAP EPS of $0.24 beats by $0.10, revenue of $12.51M beats by $0.31M |